Chemosensitivity Predicted by BluePrint 80-Gene Functional Subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)
A diagnostic gene profile for molecular subtyping of breast cancer associated with treatment response
PID: 21814749, COI: 1:CAS:528:DC%2BC38XmtlOlurY%
Krijgsman O, Roepman P, Zwart W, et al. A diagnostic gene profile for molecular subtyping of breast cancer associated with treatment response. Breast Cancer Res Treat. 2012;133:37–47.
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013;24(9):2206–23.
Molecular subtyping of early-stage breast cancer identifies a group of patients who do not benefit from neo-adjuvant chemotherapy
PID: 237566
Gluck S, De Snoo F, Peeters J, Stork-Sloots L, Somlo G. Molecular subtyping of early-stage breast cancer identifies a group of patients who do not benefit from neo-adjuvant chemotherapy. Breast Cancer Res Treat. 2013;139(3):759–67.
Pathological assessment of discordant cases for molecular (BluePrint and MammaPrint) versus clinical subtypes for breast cancer among 621 patients from the EORTC 10041/BIG 3-04 (MINDACT) trial
Viale G, Slaets L, de Snoo F, et al. Pathological assessment of discordant cases for molecular (BluePrint and MammaPrint) versus clinical subtypes for breast cancer among 621 patients from the EORTC 10041/BIG 3-04 (MINDACT) trial. Cancer Res. 2012;72(24 Suppl):303s.
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer
PID: 210378
Hammond ME, Hayes DF, Wolff AC, Mangu PB, Temin S. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Oncol Pract. 2010;6(4):195–7.
Assignment of tumor subtype by genomic testing and pathologic-based approximations: implications on patient’s management and therapy selection
Romero A, Prat A, García-Sáenz JA, et al. Assignment of tumor subtype by genomic testing and pathologic-based approximations: implications on patient’s management and therapy selection. Clin Transl Oncol. 2012;16(4):386–94.
PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers
PID: 23035882, COI: 1:CAS:528:DC%2BC38Xhslehsr
Bastien RR, Rodríguez-Lescure Á, Ebbert MT, et al. PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers. BMC Med Genomics. 2012;5:44.
Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers
PID: 22527112, COI: 1:CAS:528:DC%2BC38XhtFOkur
Nahta R, O’Regan RM. Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers. Breast Cancer Res Treat. 2012;135(1):39–48.
Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1 % to 10 % ER-positive by immunohistochemistry
PID: 222910
Iwamoto T, Booser D, Valero V, et al. Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1 % to 10 % ER-positive by immunohistochemistry. J Clin Oncol. 2012;30(7):729–34.
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014. doi:10.1016/S0140-6736(13)62422-8.
